U.S. License Holder:
Sanofi Synthelabo
Date of License:
July-12-2002
Last Update:
Sep-30-2024
FDA-Approved Indications
ELITEK (rasburicase) is a recombinant urate-oxidase indicated for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.